Across TCGA pan-cancer cohorts, NOMO2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NOMO2 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NOMO2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NOMO2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where NOMO2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.956	0.658	.002	13	view →
PDAC	DFS	Median	All	0.831	0.680	.005	11	view →
LSCC	DFS	Median	All	0.866	1.000	.010	9	view →
LUAD	DFS	Tertile	All	0.849	0.281	.010	7	view →
HNSC	DFS	Quartile	III,IV	1.000	0.696	.019	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: NOMO2 tumor-vs-normal RNA expression · all NOMO2 data types